Literature DB >> 5482325

L-dopa treatment failure: explanation and correction.

L Rivera-Calimlim, C A Dujovne, J P Morgan, L Lasagna, J R Bianchine.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5482325      PMCID： PMC1819624          DOI： 10.1136/bmj.4.5727.93

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  5 in total

1.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

2.  L-dopa in postencephalitic parkinsonism.

Authors:  D B Calne; G M Stern; D R Laurence; J Sharkey; P Armitage
Journal:  Lancet       Date:  1969-04-12       Impact factor: 79.321

3.  Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase.

Authors:  G Bartholini; A Pletscher
Journal:  J Pharmacol Exp Ther       Date:  1968-05       Impact factor: 4.030

4.  Metabolic studies and clinical observations during L-dopa treatment of Parkinson's disease.

Authors:  M J Peaston; J R Bianchine
Journal:  Br Med J       Date:  1970-02-14

5.  Treatment of Parkinsonism with Laevo-dopa.

Authors:  C Mawdsley
Journal:  Br Med J       Date:  1970-02-07
  5 in total
  22 in total

1.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Authors:  D Deleu; G Ebinger; Y Michotte
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  The effect of an antacid on the bioavailability of indomethacin.

Authors:  R L Galeazzi
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

3.  Plasma dopa concentrations after different preparations of levodopa in normal subjects.

Authors:  J G Morris; R L Parsons; J R Trounce; M J Groves
Journal:  Br J Clin Pharmacol       Date:  1976-12       Impact factor: 4.335

Review 4.  Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management.

Authors:  W H Jost
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 5.  Parkinson's disease and levodopa. A five-year follow-up and review.

Authors:  C H Markham; L J Treciokas; S G Diamond
Journal:  West J Med       Date:  1974-09

Review 6.  Augmenting the action of levodopa.

Authors:  S K Rao; S D Vakil; D B Calne; A Hilson
Journal:  Postgrad Med J       Date:  1972-11       Impact factor: 2.401

Review 7.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

Review 8.  Antiparkinsonian drugs: pharmacological and therapeutic aspects.

Authors:  D B Calne; J L Reid
Journal:  Drugs       Date:  1972       Impact factor: 9.546

Review 9.  Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes.

Authors:  R L Parsons
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

Review 10.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.